Second-line switch to dolutegravir noninferior in HIV
For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue ...
Jun 23, 2023
0
2